Why the study?
What are the recent advances in preventing anthracycline-induced cardiotoxicity in children?
Population
Children receiving anthracycline cancer chemotherapy
Design
Review
Authors
Loading...
Supports short-term dexrazoxane use in children on anthracyclines; leaves open long-term cardiac protection pending prospective trials.
What are the recent advances in preventing anthracycline-induced cardiotoxicity in children?
Dexrazoxane and other strategies offer short-term cardioprotection against anthracycline toxicity in children, but long-term outcomes require further study.
Iarussi et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: